Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-08-28 17:40:02 ET · period of report 2026-08-27 · accession 0001628280-26-059444 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-28 17:40 | 2026-08-27 | ARQT | Curran Terrie | Dir | M - OptEx | $8.30 | +38.2K | 50.6K | +309% | +$317.2K |
| DM | 2026-08-28 17:40 | 2026-08-27 | ARQT | Curran Terrie | Dir | S - Sale+OE | $25.03 | -38.2K | 23.5K | -62% | -$956.1K |
| DM | 2026-08-28 17:40 | 2026-08-27 | ARQT | Curran Terrie | Dir | M - OptEx | $0.00 | -38.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-27 | M | A | 11,148 | $7.51 | 34,674 | D | — | — | (F1) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. |
| 2 | Common | Common Stock | 2026-08-27 | S | D | 11,148 | $25.03 | 23,526 | D | — | — | (F1) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-08-27 | M | A | 27,052 | $8.63 | 50,578 | D | — | — | (F3) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. |
| 4 | Common | Common Stock | 2026-08-27 | S | D | 27,052 | $25.03 | 23,526 | D | — | — | (F3) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 5 | Derivative | Stock Option (right to buy) | 2026-08-27 | M | D | 11,148 | $0.00 | 0 | D | $7.51 · — to 2033-05-31 | 11,148 Common Stock | (F1) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. (F4) The option is fully vested. |
| 6 | Derivative | Stock Option (right to buy) | 2026-08-27 | M | D | 27,052 | $0.00 | 0 | D | $8.63 · — to 2034-06-14 | 27,052 Common Stock | (F3) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. (F4) The option is fully vested. |